UnitedHealth Group Incorporated (UNH) Stock Price & Analysis
UnitedHealth Group Incorporated (UNH) closed at USD 424.98 on Thursday, October 22, 2026, up 1.91% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 417; the Oct 22, 2026 session ranged USD 417.13–426.55 on volume of 5,417,260 shares. Market capitalization is $381.46B, with a 52-week range of USD 255.97–461.62 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/UNH.md
Latest Earnings Results (UNH)
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $4.69 (adjusted (non-GAAP) diluted) | $112.69B | Oct 13, 2026, 6:14:45 AM ET · on Nexqual +38 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (UNH)
- Last four reported quarters (through Jun 30, 2026): revenue $450B, net income $14.1B (3.1% margin), free cash flow $23.6B (SEC filings).
- Valuation: P/E 27.0x (avg 26.5x at the last 3 fiscal year-ends), EV/EBITDA 16.3x, net debt $41.9B.
- 17 of 80 tracked superinvestors hold UNH (13F, Q2 2026): 2 new, 6 added, 9 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $945K; 3 not under a Rule 10b5-1 plan ($945K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.96 on a 1–5 scale) (26 analysts), mean target USD 478.12 (range 380–529).
- Total return with dividends: 1Y +21.0% vs S&P 500 +14.9%; 5Y +3.6% vs S&P 500 +80.3%.
- Next earnings: 2027-01-12, EPS estimate USD 2.26, revenue estimate $112B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (UNH)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $288B | $324B | $372B | $400B | $448B | $450B |
| Gross profit | $257B | $290B | $333B | $354B | $397B | — |
| Operating income | $24.0B | $28.4B | $32.4B | $32.3B | $19.0B | $21.7B |
| Net income | $17.3B | $20.1B | $22.4B | $14.4B | $12.1B | $14.1B |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 | — |
| Free cash flow | $19.9B | $23.4B | $25.7B | $20.7B | $16.1B | $23.6B |
| Gross margin | 89.2% | 89.6% | 89.6% | 88.3% | 88.7% | — |
| Operating margin | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% | 4.8% |
| Net margin | 6.0% | 6.2% | 6.0% | 3.6% | 2.7% | 3.1% |
| Revenue growth | +11.8% | +12.7% | +14.6% | +7.7% | +11.8% | — |
| Cash + short-term investments | $23.9B | $27.9B | $29.6B | $29.1B | $28.1B | — |
| Total debt | $46.0B | $57.6B | $62.5B | $76.9B | $78.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (UNH)
P/E 27.0x · P/S 0.8x · EV/EBITDA 16.3x · EV/Sales 0.9x · P/FCF 16.2x · P/B 3.6x · FCF yield 6.19% · Earnings yield 3.70% · Dividend yield (paid, TTM) 2.12% · Buyback yield (TTM) 0.43% · Net debt $41.9B · EV $423B
P/E at fiscal year-ends: Dec 2025 24.9x, Dec 2024 32.6x, Dec 2023 22.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (UNH)
17 of 80 tracked investors hold UNH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Samantha McLemore | Patient Capital Management | 6.05% | $182M | Added +0.1% |
| Ruane Cunniff | Ruane Cunniff LP | 4.56% | $293M | Reduced -3.1% |
| Van Den Berg Management I | 2.43% | $11.5M | Reduced -4.2% | |
| Christopher Davis | Davis Advisors | 2.28% | $530M | Added +2.2% |
| Mairs & Power | Mairs & Power Funds | 2.14% | $233M | Reduced -24.4% |
| Dodge & Cox Funds | Dodge & Cox | 1.97% | $3.77B | Reduced -4.2% |
| Hillman Capital | Hillman Capital Management | 1.63% | $2.2M | Reduced -27.0% |
| Yacktman Asset Management | 0.88% | $71.4M | Added +2.0% | |
| Duan Yongping | H&H International Investment | 0.87% | $166M | Reduced -33.6% |
| Vulcan Value Partners | 0.85% | $28.0M | Reduced -92.6% | |
| Chase Coleman | Tiger Global Management | 0.52% | $124M | Reduced -15.1% |
| Sarah Ketterer | Causeway Capital Management | 0.39% | $36.3M | Added +21.7% |
| Tweedy Browne | 0.13% | $1.7M | Added +11.5% | |
| Torray Funds | 0.04% | $284K | New position | |
| First Eagle Investment | First Eagle Investment Management | 0.03% | $17.6M | Added +3.8% |
| Jensen Investment Management | 0.01% | $357K | Reduced -42.4% | |
| Glenn Greenberg | Brave Warrior Advisors | <0.01% | $207K | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (UNH)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Conway Patrick Hugh | Chief Executive Officer, Optum | 1,169 | $456K | 7.1% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-05 | Conway Patrick Hugh | Chief Executive Officer, Optum | 500 | $205K | 2.9% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-23 | Conway Patrick Hugh | Chief Executive Officer, Optum | 800 | $284K | 4.3% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (UNH)
Consensus Buy (mean 1.96 on a 1–5 scale), 26 analysts; mean target USD 478.12 (low 380, high 529).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Mizuho | Target raised | Outperform | $493 → $500 |
| 2026-10-20 | RBC Capital | Target raised | Outperform | $478 → $498 |
| 2026-10-16 | Bernstein | Target lowered | Outperform | $512 → $500 |
| 2026-10-16 | JP Morgan | Target raised | Overweight | $516 → $524 |
| 2026-10-15 | TD Cowen | Reiterated | Hold | $402 |
| 2026-10-14 | Piper Sandler | Target raised | Overweight | $502 → $504 |
| 2026-10-14 | Barclays | Target lowered | Overweight | $441 → $440 |
| 2026-10-14 | Baird | Target lowered | Neutral | $453 → $427 |
| 2026-10-09 | TD Cowen | Target lowered | Hold | $430 → $402 |
| 2026-07-21 | JP Morgan | Target raised | Overweight | $466 → $516 |
| 2026-07-21 | Mizuho | Target raised | Outperform | $470 → $493 |
| 2026-07-20 | Barclays | Target raised | Overweight | $429 → $441 |
Total return (dividends reinvested) (UNH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +21.0% | +3.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +21.1% | +0.7% |
| Volatility (annualized) | 36.0% | 35.0% |
| Max drawdown | -28.6% (Oct 2025→Mar 2026) | -60.8% (Nov 2024→Jul 2025) |
UNH revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UnitedHealthcare | $86.02B | 76.8% | -0.1% |
| Optum | $65.66B | 58.6% | -2.3% |
| Optum Rx | $38.29B | 34.2% | -0.4% |
| Optum Health | $23.47B | 21.0% | -5.1% |
| Optum Insight | $5.40B | 4.8% | +3.2% |
| Total revenue | $112.03B | 100% | — |
UNH revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $13.84B | 12.3% | +2.0% |
| Service | $10.02B | 8.9% | +10.8% |
| Total revenue | $112.03B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name UNH in their SEC reports
| Relationship to UNH | Company | Filing | Sentence |
|---|---|---|---|
| partner | CREDICORP LTD (BAP) | 20-F Apr 27, 2026 | “In 2018, UnitedHealth Group, one of the world's largest healthcare companies, acquired Banmédica, becoming Pacífico's new partner in Peru.” |
| partner | DarioHealth Corp. (DRIO) | 10-K Mar 19, 2026 | “Prior to Chicago Pacific Partners, Mr. Leisure held senior management roles at Accenture, PricewaterhouseCoopers, Towers Perrin, Kaiser Foundation Health Plans and UnitedHealth Group.” |
| competitor | HEALTHEQUITY, INC. (HQY) | 10-K Mar 17, 2026 | “Some of our direct competitors (including well-known retail investment companies, such as Fidelity Investments, and healthcare service companies such as UnitedHealth Group's Optum and Webster Bank) are in a position to devote more resources to the development, sale and support of their products and services than we have at our disposal.” |
| competitor | Astrana Health, Inc. (ASTH) | 10-K Mar 12, 2026 | “In the greater Los Angeles area, such competitors include Regal Medical Group and Lakeside Medical Group, which are part of Heritage Provider Network ("Heritage"), as well as Optum, a subsidiary of UnitedHealth Group.” |
| partner | BrightSpring Health Services, Inc. (BTSG) | 10-K Feb 27, 2026 | “The Company entered into a purchase agreement with Amedisys, Inc., UnitedHealth Group Incorporated and certain of their respective subsidiaries, to purchase certain Amedisys home health and hospice care centers and certain UnitedHealth Group care centers (the "Amedisys and LHC Branches Acquisition"), which is comprised of 110 branches, for a total purchase price of $246.4 million, net of cash acquired.” |
| competitor | Option Care Health, Inc. (OPCH) | 10-K Feb 24, 2026 | “The Company's competitors within the home infusion market include Optum Infusion Pharmacy (a unit of UnitedHealth Group), Coram CVS/specialty infusion services (a division of CVS Health), Amerita Specialty Pharmacy (a division of BrightSpring Health), KabaFusion, Soleo Health, Vital Care and many other regional and local home infusion companies, ambulatory infusion centers, or specialty pharmacies including Accred…” |
| competitor | AdaptHealth Corp. (AHCO) | 10-K Feb 24, 2026 | “In addition, pharmacy benefit managers, including CVS Health Corporation and the Optum business of UnitedHealth Group Incorporated, have entered the HME market and compete with AdaptHealth.” |
| competitor | IQVIA HOLDINGS INC. (IQV) | 10-K Feb 17, 2026 | “Our offerings compete with various firms, including Accenture, Aetion (a Datavant company), Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, …” |
| competitor | CVS HEALTH Corp (CVS) | 10-K Feb 10, 2026 | “The Health Services segment has a significant number of competitors offering PBM services, including large, national PBM companies (e.g., Prime Therapeutics and MedImpact), PBMs owned by large national health plans (e.g., the Express Scripts business of Cigna Corporation and the Optum Rx business of UnitedHealth Group) and smaller standalone PBMs.” |
| competitor | MOLINA HEALTHCARE, INC. (MOH) | 10-K Feb 10, 2026 | “Our primary competitors in the Medicaid managed care industry include Centene Corporation, CVS Health Corporation, Elevance Health, Inc., UnitedHealth Group Inc., and large not-for-profit healthcare organizations.” |
| competitor | DLH Holdings Corp. (DLHC) | 10-K Dec 10, 2025 | “Our competitors include operating units within: Accenture Federal Services LLC, BAE Systems plc, Booz Allen Hamilton Holding Corp., CACI International, Inc., Deloitte, ECS Federal, LLC, The Emmes Company, LLC, General Dynamics Information Technology, Inc., Guidehouse, IBM Federal, ICF International, Inc., Information Management Services, Inc., Leidos Holdings, Inc., LMI Consulting, LLC, ManTech International Corp.…” |
UNH company outlook (results filed Oct 13, 2026)
- “Outlook to At Least $19.50 Per Share;”
- “The company now expects full year 2026 adjusted net earnings of at least $20.50 per share, incorporating experience through the third quarter 2026.”
Quoted word-for-word from the SEC 8-K results press release.
UNH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $2.26 | $2.17 | +4.1% | $112.34B | 22 |
| Next quarter (ends Mar 2027) | $8.18 | $8.12 | +0.6% | $113.70B | 16 |
| Current fiscal year (ends Dec 2026) | $20.59 | $19.81 | +3.9% | $448.95B | 24 |
| Next fiscal year (ends Dec 2027) | $23.27 | $22.44 | +3.7% | $463.61B | 26 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 424.98 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 417 |
| Open | USD 418.38 |
| Day Range | USD 417.13 – 426.55 |
| 52-Week Range | USD 255.97 – 461.62 |
| Volume | 5,417,260 shares |
| Market Cap | $381.46B |
| Exchange | NYQ |
Technical Analysis (UNH)
Nexqual's technical model rates UNH "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.62 (overbought) |
| vs SMA50 | Above (USD 388.19) |
| MACD | 8.89 (positive) |
Analyst Ratings (UNH)
Wall Street analysts rate UNH "Buy" based on 26 analysts, with a mean price target of USD 478.12 (range USD 380–529), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 478.12 |
| High Target | USD 529 |
| Low Target | USD 380 |
| Buy / Hold / Sell | 21 / 5 / 0 |
Earnings (UNH)
| Next Earnings Date | 2027-01-12 |
|---|---|
| EPS Estimate | USD 2.26 |
| Revenue Estimate | $112.34B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 4.69 vs est 4.14 ▲ beat |
| 2026-06-30 | USD 6.38 vs est 4.92 ▲ beat |
| 2026-03-31 | USD 7.23 vs est 6.6 ▲ beat |
| 2025-12-31 | USD 2.11 vs est 2.11 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (UNH)
| Total Revenue | $450.06B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.40% |
| Gross Margin | +20.05% |
| Operating Margin | +5.82% |
| Profit Margin | +3.53% |
| ROE | +15.77% |
| Debt / Equity | 0.7 |
| Current Ratio | 0.74 |
| Total Cash | $28.55B |
| Total Debt | $74.33B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $23.62B (5.2% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (UNH)
Nexqual rates UnitedHealth Group Incorporated's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 20%, operating 6% (last 12 months) |
| Balance Sheet | Mixed — $31.5B cash and investments vs $73.3B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $23.6B (last 4 quarters to Jun 2026, SEC), 5% margin |
| Efficiency | Solid — ROE 16%, ROA 5.2% |
Ownership (UNH)
| Insider Ownership | +0.25% |
|---|---|
| Institutional Ownership | +89.61% |
| Shares Outstanding | 897.59M |
| Float | 899.41M |
| Short % of Float | +1.98% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (UNH)
UnitedHealth Group Incorporated is led by Stephen J. Hemsley, CEO & Non-Independent Non-Executive Chairman, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO & Non-Independent Non-Executive Chairman | Stephen J. Hemsley |
|---|---|
| Chief Financial Officer | Wayne Scott DeVeydt |
| Senior Vice President of Capital Markets Communications & Investor Relations | Zachary William Sopcak |
Major Backers & Investors (UNH)
Notable institutional backers of UnitedHealth Group Incorporated include Capital Group, FMR, LLC, Price (T.Rowe) Associates Inc, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 3.33% |
| FMR, LLC | 3.12% |
| Price (T.Rowe) Associates Inc | 2.58% |
| JPMorgan | 2.26% |
| Charles Schwab Investment Management, Inc. | 2.21% |
| Charles Schwab | 1.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.34% |
| BlackRock | 8.56% |
| State Street | 5.08% |
| Geode Capital | 2.42% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From UnitedHealth Group Incorporated's Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- The ability to analyze complex data and apply deep health care expertise and insights allows us to serve patients, consumers, care providers, businesses, communities and governments with more innovative products and complete, end-to-end offerings for many of the biggest challenges facing health care today.
- Optum Financial, including Optum Bank, serves consumers through nearly 26 million consumer accounts with more than $27 billion in assets under management as of December 31, 2025.
- Provides health care coverage for seniors and other eligible Medicare beneficiaries through the Medicare Advantage program administered by the Centers for Medicare & Medicaid Services (CMS), including Medicare Advantage HMO plans, Preferred Provider Organization (PPO) plans, Point-of-Service plans, Private-Fee-for-Service plans and Special Needs Plans (SNPs).
- UnitedHealthcare Community & State's primary customers oversee Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs (CHIP); Dual SNPs (DSNPs); Long-Term Services and Supports (LTSS); Aged, Blind and Disabled; and other federal, state and community health care programs.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business activities in the United States and other countries are highly regulated and new laws or regulations or changes in existing laws or regulations or their enforcement or application could materially and adversely affect our business.
- Our pharmacy care services businesses face regulatory and operational risks and uncertainties which may differ from the risks of our other businesses.
- We are routinely made party to a variety of private party and governmental legal actions and investigations related to, among other matters, the design, management and delivery of our product and service offerings. Any failure by us to adhere to the laws and regulations applicable to our businesses could subject us to civil and criminal penalties.
- Risks Related to the Regulation of Our Business
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CVS | CVS Health Corporation | USD 94.48 | ▲ 1.1% |
| ELV | Elevance Health, Inc. | USD 445.28 | ▲ 2.57% |
| CI | The Cigna Group | USD 315.88 | ▲ 3.78% |
| HUM | Humana Inc. | USD 420.97 | ▼ 1.05% |
| CNC | Centene Corporation | USD 71.24 | ▲ 1.42% |
| MOH | Molina Healthcare Inc | USD 216.64 | ▲ 0.81% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt